Strategic focus on MedTech partnerships and infection prevention technology drove revenue and EBITDA growth in 2024, with ambitious targets set for 2030. Addressable markets exceed USD 74 billion across key therapeutic areas.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.